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ABSTRACT  1 
Objectives 2 
To investigate the influence of vasodilator drugs on the occurrence of features depending 3 
on myocardial ischemia/fibrosis  4 
(ventricular arrhythmias, Q waves, cardiac blocks, pacemaker implantation, left ventricular 5 
ejection fraction -LVEF-<55% and/or congestive heart failure and sudden cardiac death) in 6 
Systemic Sclerosis (SSc).                        7 
Methods 8 
Six hundred and 1 SSc patients were enrolled from December 1st, 2012 to November 30th, 9 
2015 and had a second visit 0.5-4 years apart. 153 received no vasodilators; 448 received 10 
vasodilator therapy, (i.e. Calcium Channel Blockers and/or Angiotensin Converting 11 
Enzyme inhibitors or Angiotensin II receptor blockers or combinations of them), 89 of them 12 
being also treated with either endothelin receptor antagonists or PDE5 inhibitors or 13 
prostanoids. Associations between the occurrence of myocardial disease manifestations 14 
and any demographic, disease and therapeutic aspect were investigated by Cox 15 
regression analysis. A Cox frailty survival model with centre of enrollment as a random 16 
effect was performed. 17 
Results 18 
During 914 patient/follow-up years, 12 ventricular arrhythmias, 5 Q waves, 40 cardiac 19 
blocks, 6 pacemaker implantations, 19 reduced LVEF and/or CHF occurred. In multivariate 20 
Cox regression analysis, vasodilator therapy was associated with a lower incidence of 21 
ventricular arrhythmias (p=0.03); low dose acetylsalycilic acid (ASA) with a  lower 22 
incidence of cardiac blocks and/or Q waves and/or pacemaker implantation (p=0.02), 23 
active disease with a higher incidence of LVEF<55% and/or CHF and cardiac blocks 24 
and/or Q waves and/or pacemaker implantation (p=0.05). 25 
Conclusions 26 
The present study might suggest a preventative effect on the occurrence of distinct 27 
myocardial manifestations by vasodilator therapy and low dose ASA.  28 
 29 
Keywords: primary myocardial disease in scleroderma, preventative role of vasodilator 30 
therapy.   31 
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INTRODUCTION 1 
Myocardial disease occurring in patients with Systemic Sclerosis (SSc) is classically 2 
subdivided into primary and secondary, depending the absence or, respectively, 3 
coexistence of pulmonary and/or renal involvement.[1-3]  4 
Primary myocardial disease is morphologically characterized by vasculopathy of small 5 
arteries and biventricular patchy myocardial fibrosis which presents a strong association 6 
with contraction band necrosis, suggesting the implication of ischemia-reperfusion events 7 
i.e. a myocardial Raynaud’s phenomenon (RP).[4] In this regard, short term trials and 8 
retrospective observational studies have underlined a beneficial effect of calcium channel 9 
blockers (CCB), angiotensin converting enzyme inhibitors (ACEinh) on cardiac 10 
vascularization and function.[5-11]  11 
By now, the role of vasodilator agents in the prevention of primary myocardial disease in 12 
SSc has not yet been clarified. In order to define the management of SSc, a project named 13 
DeSScipher (To decipher the optimal treatment of SSc) was submitted to and funded by 14 
the European Community (FP7- HEALTH n°305495). Here, we report the results of the 15 
subproject devoted to investigate the influence of vasodilator drugs on the occurrence of 16 
primary myocardial complications, specifically those associated with a poor prognosis i.e. 17 
ventricular arrhythmias, Q waves , cardiac blocks , pacemaker  implantation , reduced left 18 
ventricular ejection fraction (LVEF), congestive heart failure (CHF) and sudden cardiac 19 
death.[1-3,12-14] 20 
 21 
METHODS 22 
Patients and study design 23 
Patients fulfilling the ACR/EULAR criteria for SSc,[15] consecutively admitted to 20 24 
DeSScipher-EUSTAR centres from December 1st, 2012 to November 30th, 2015, were 25 
enrolled, according to local ethical requirements.  26 
Patients with the following characteristics were excluded: significant pulmonary 27 
parenchymal (forced vital capacity and/or diffusing lung capacity for CO < 70%) or 28 
vascular involvement (estimated systolic pulmonary arterial pressure > 40 mmHg), 29 
intestinal involvement (malabsorption syndrome or paralytic ileus or renal involvement 30 
(serum creatinine level >1.2 mg/dl and/or dialysis or  previous scleroderma renal crisis) or 31 
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any sign/symptom/ electrocardiographic (ECG) finding of  myocardial disease, basal 1 
pulmonary rales and/or leg edema indicative of congestive heart failure. 2 
Patients enrolled in the study were investigated according to the DeSScipher protocol, 3 
shared by all participating centres. In particular, they were assessed for the items listed in 4 
the European Scleroderma Trials and Research group (EUSTAR) protocol,[16] including 5 
European Scleroderma Study Group (EScSG) activity criteria.[17] Moreover, as far as 6 
myocardial disease is concerned, each patient was examined at baseline by means of 7 
medical history, clinical examination, ECG, Holter ECG and B-mode echocardiography at 8 
baseline, and was reassessed every 3 months with respect to medical history, clinical 9 
examination, and ECG, and every 6 months by Holter ECG and B-mode echocardiography 10 
until the end of each follow-up-year. According to local policies, patients had to undergo 11 
either standard vasodilator therapy i.e. CCB such as nifedipine up to 60 mg/qd or 12 
comparable doses of other drugs of the same class and/or ACEinh such as captopril up to 13 
100 mg/qd, or no vasodilator therapy. Two hundred and 50 patients per arm had to be 14 
enrolled. Despite the strictly defined entry criteria, 2 major protocol deviations occurred. As 15 
far as treatment is concerned, some patients with baseline myocardial disease were 16 
enrolled. As far as treatment is concerned, 63 patients undergoing AgIIrb±CCB treatment 17 
were enrolled.Because of the influence on the same pathophysiologic pathway, they were 18 
considered in the same class of ACEinh and included in the arm of those treated with CCB 19 
and/or ACEinh, with the whole group being referred to as standard vasodilator therapy. 20 
Moreover, some patients treated with targeted vasodilator drugs (i.e. prostanoids or 21 
endothelin receptor antagonists or phosphodiesterase type 5 inhibitors), were enrolled. 22 
Out of them, those undergoing standard vasodilator therapy were included in the same 23 
arm which was referred to as vasodilator therapy; those treated with targeted vasodilator 24 
drugs only were excluded because of the intermittent drug regimen in most of them. The 25 
role of other features potentially influencing the occurrence of cardiac disease during 26 
follow-up was also investigated i.e. diffuse subset, disease activity, digital ulcers,  27 
traditional risk factors such as sex, cigarette smoking, systemic arterial hypertension, 28 
hypercholesterolemia and drugs including ongoing corticosteroids ± immunosuppressive 29 
therapy and low dose acetylsalycilic acid (ASA) (≤325 mg daily).[1-3,18-21] 30 
Follow-up and outcome measures 31 
The new occurrence of ventricular arrhythmias as manifestations indicative of myocardial 32 
ischemia, that of Q waves and/or cardiac blocks and/or pacemaker implantation as 33 
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manifestations indicative of myocardial fibrosis or a therapeutic intervention promoted by it,  1 
and that of LVEF<55% and/or CHF, as manifestations of evolved disease, were 2 
investigated.[1-4]   3 
Finally, the incidence of withdrawal from treatment was used as safety endpoint. 4 
Statistical analysis 5 
StataMP 13, IBM SPSS 24.0 and MedCalc 11.3 for Windows software were used for 6 
statistical analyses. Continuous data were expressed as means and standard deviations 7 
(SD) and compared by t student test. The predictivity of myocardial disease occurrence by 8 
each distinct feature was assessed by Cox proportional hazard regression models. The 9 
number of covariates to be included in the multivariate model was defined by using a ratio 10 
of cases per covariate in the size of 10.[24] Moreover, in order to address the potential 11 
influence of different therapeutic strategies by clinician from different centres, we carried 12 
out a Cox frailty survival model with centre of enrollment as random effect.[25] Statistical 13 
significance was set at P <0.05. 14 
 15 
RESULTS 16 
Patients 17 
From December 1st, 2012 to November 30th, 2015, a total of 654 SSc patients, with a 18 
mean age of 56±13 years  a disease duration from the first non-RP manifestation ranging 19 
from 0.5 to 61 years (mean 10±9 SD), were enrolled in the study and followed-up for at 20 
least six months.  21 
One hundred and 53 patients did not undergo any vasodilator; 448 were prescribed 22 
vasodilators including 89 treated with either prostanoids and/or endothelin receptor 23 
antagonists and/or phosphodiesterase inhibitors. The 43 patients treated only with 24 
targeted vasodilators were excluded.  25 
Table 1 shows the demographic, clinical, serological and therapeutic features as assessed 26 
at enrollment and during follow-up as far as the drug regimen is concerned, in the 27 
remaining 601 patients subdivided according to the therapeutic subgroup. Given the 28 
presence of missed items, the prevalence of each feature has been calculated among 29 
patients in whom it had been underlined. Hypercholesterolemia was noticed in few 30 
patients; no data were available for statin use.                                                                                                                                                                   31 
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With respect to patients undergoing no vasodilators, those treated with vasodilator therapy 1 
resulted to be more frequently aged ≥50 years (p=0.005), affected by systemic arterial 2 
hypertension (p<0.001) and to be undergoing in a greater percentage corticosteroids 3 
±immunosuppressors (p<0.001) and low dose ASA  (p<0.001) i.e. they presented a 4 
greater prevalence of disease features potentially associated with a worse cardiovascular 5 
outcome. 6 
 7 
                                                                                                                                                          8 
Table 1. Demographic, clinical, serological and therapeutic features of the 601 9 
SSc patients subdivided according to the treatment subgroup        10 
FEATURES No vasodilators 
(n=153) 
Vasodilator therapy 
(n=448) 
P 
Female Sex 134/153 (87%) 395/448 (88%) 0.88 
Age (mean±SD) years 55±14 57±13 0.21 
Age ≥ 50 years 95/153 (62%) 332/448 (74%) 0.005 
Early disease 53/145 (36%) 148/428 (35%) 0.69 
Clinical subset    
Limited cutaneous 124 (81%) 348 (78%) 0.42 
Diffuse cutaneous 29 (19%) 100 (22%) 0.42 
Serological subset  
Antinuclear antibodies (ANA) 
positive 
Anti-centromere (ACA) positive 
Anti-Scl-70 positive 
 
134/137 (98%) 
 
64/137 (47%) 
39/130 (30%) 
 
400/410 (98%) 
 
163/410 (42%) 
136/388 (35%) 
 
0.99 
 
0.16 
0.33 
Further aspects    
Baseline Myocardial 18/123 (15%) 56/353 (16%) 0.27 
Disease    
Digital ulcers (ever) 50/149 (33%) 168/437 (38%) 0.33 
Tendon friction rubs 7/148 (5%) 20/432 (5%) 0.99 
Arthritis 18/153 (12%) 52/442 (12%) 0.99 
EScSG activity index≥3 13/153 (8%) 41/448 (9%) 0.87 
Systemic arterial 0/153 139/448 (31%) <0.001 
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 1 
Occurrence of myocardial disease features during follow-up 2 
During 914 follow-up patient/years, ventricular arrhythmias developed in 12 patients; Q 3 
waves developed in 5, cardiac blocks in 40, a Pacemaker was implanted in 6; 15 4 
developed a LVEF<55% and/or a CHF. No patient underwent a sudden cardiac death.                                                                               5 
In univariate analysis, vasodilator therapy resulted to be  associated with a nearly 6 
significant occurrence of ventricular arrhythmias  (7/285 events (2%) occurring during 709 7 
patient/years as compared to 5/97 (5%) during 206 patient/years in those not treated with 8 
any vasodilator) (HR 0.33 95%CI 0.10-104; p=0.060); low dose ASA with a reduced 9 
incidence of Q waves and/or cardiac blocks and/or pacemaker implantation (17/161 events 10 
(10%) occurring during 434 patient/years as compared to 29/182 (16%) during 383 11 
patient/years in those not treated with ASA) (HR 0.41 95%CI 1.98-16.56; p=0.004). On the 12 
contrary, male sex (HR 5.73; 95%CI 1.98-16.56; p=0.002) and a EScSG activity index ≥ 3 13 
at the enrollment into the study (HR=4.83; 95%CI 1.52-15.34;p=0.008) were found to 14 
predict the development of a LVEF<55% and/or CHF.  15 
In order to perform the multivariate Cox regression analysis, five covariates were selected 16 
because of their potential value in influencing the occurrence of cardiac events over time. 17 
Several tentatives were performed by selecting, according to the number of the events 18 
occurred, all the 5 covariates were considered for cardiac blocks and/or Q waves and/or 19 
pacemaker implantation; 2 covariates for ventricular arrhytmias; 2 covariates for 20 
LVEF<55% and or CHF. Table 2 shows the results of this approach: vasodilator therapy 21 
resulted to be associated with a lower incidence of ventricular arrhythmias (HR 0.28; 95% 22 
CI 0.09-0.90; p=0.03); low dose ASA with a lower incidence of cardiac blocks and/or Q 23 
waves and/or pacemaker implantation  (HR 0.46; 95% CI 0.24-0.87; p=0.02) ; a EScSG 24 
activity index≥3 with a higher occurrence of a LVEF<55% and/or CHF (HR 3.71; 95% CI 25 
1.02-13.42;p= 0.05) and cardiac blocks and/or Q waves and/or pacemaker implantation 26 
Hypertension    
Cigarette smoking ever 
Hypercholesterolemia 
39/127 (31%) 
0/7 
88/350 (25%) 
0/23 
0.24 
- 
Ongoing corticosteroids ± 
immunosuppressors 
 
44/145 (30%) 
 
215/408 (53%) 
 
<0.001 
Ongoing low dose acetylsalicylic 
acid 
 
28/146 (19%) 
 
205/377 (54%) 
 
<0.001 
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(HR 2.15; 95% CI 1.00-4.63; p=0.05). Moreover, an unfavourable role of male sex 1 
emerged.    2 
Finally, since therapeutic strategies can differ among distinct centres, a Cox frailty survival 3 
model with center of enrollment as random effect, was performed (Table 3). The 4 
associations of vasodilators, low dose ASA and an EScSG activity index≥3 were 5 
confirmed. 6 
 7 
Table 2. Associations detected for each outcome measure by multivariate Cox 8 
regression analysis 9 
COVARIATES Cardiac Blocks and/or Q 
waves and/or 
Pacemaker Implantation      
n.events=49* 
 
HR; 95%CI; p 
Ventricular Arrhytmias             
n. events=12 
 
 
 
HR: 95%CI; p 
LVEF≤ 55%                   
and/or CHF                      
n.events=19 
 
 
HR: 95%CI; p 
Male sex  - 5.70: 2.20-18.9; 
<0.001 
Age≥50    - 
EScSG activity 
index ≥3 
2.15; 1.00-4.63; 0.05 - 3.71; 1.02-
13.42; 0.05 
Low dose ASA 0.46; 0.24-0.87; 0.02 -  
Vasodilators  0.28; 0.09-0.90; 0.03 - 
*Two patients developed 2 events (1 Cardiac Block and Pacemaker Implantation; 1 10 
Cardiac Block and/or Q wave) 11 
---------------------------------------------------------------------------------------------------- 12 
 13 
Table 3. Associations detected for each outcome measure by Cox frailty 14 
analysis 15 
COVARIATES Cardiac Blocks  
and/or Q waves 
and/or Pacemaker 
Implantation       
n.events=49* 
HR; 95%CI; p 
Ventricular Arrhytmias  
 
 
n. events=12 
HR; 95%CI; p 
LVEF≤ 50%                   
and/or CHF 
 
                     
n.events=19                               
HR; 95%CI; p 
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EScSG activity 
index ≥3 
2.12; 0.98-4.57; 0.06 - 3.79; 1.04-13.82; 
0.04 
Low dose ASA 0.53; 0.26-1.08; 0.08 -              - 
Vasodilators - 0.32; 0.10-1.02; 0.05 - 
 * Two patients developed 2 events (1 Cardiac Block and Pacemaker Implantation; 1 1 
Cardiac Block and/or Q wave) 2 
 3 
 4 
Withdrawal from vasodilator therapy and low dose ASA                                                                                5 
Ninety-three out of the 448 patients undergoing vasodilator therapy withdrew from 6 
treatment: 15 treated with CCB alone, 3 treated with ACEi or AngIIrb alone, none with 7 
CCB + ACEi or AngIIrb reaching an incidence of 2.1/100 patient-years; 31 treated with 8 
endothelin receptor antagonists, 19 treated with phosphodiesterase type 5 inhibitors and 9 
25 treated with prostanoids reaching an incidence of 32/100 patient-years. Moreover, 16 of 10 
the 230 patients undergoing ASA withdrew from treatment reaching an incidence rate of 11 
3/100 patient-years. 12 
 13 
DISCUSSION 14 
 To the best of our knowledge, this is the first observational, prospective, long term study 15 
to investigate the association between  vasodilator therapy and the occurrence of disease    16 
manifestations probably or potentially related to myocardial ischemia (ventricular 17 
arrhythmias), fibrosis (Q waves and/or cardiac blocks and/or pacemaker implantation) or 18 
both (reduced LVEF, congestive heart failure  and sudden cardiac death). Actually, as far 19 
as the influence of vasodilator therapy on myocardial disease is concerned, Kazzam et 20 
al.[27] only investigated diastolic and systolic function in 22 SSc patients receiving 21 
captopril treatment (1.3 mg/ kg/ daily) for 11-15 months. These authors found an increase 22 
in LVEF and a decrease in isovolumic relaxation time, indicating an improved left 23 
ventricular filling, but did not consider any of the features assessed in our study. 24 
In order to address the aim of the study, we also investigated the association between  the 25 
occurrence of  the investigated  manifestations and demographic, disease and different 26 
therapeutic aspects potentially involved in SSc cardiac disease.[1-3,18-23] After excluding 27 
any bias deriving from potential differences in the treatment policies among the distinct 28 
centres involved in the study, vasodilators were found to be associated with a lower 29 
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incidence  of ventricular arrhythmias, low dose ASA with a nearly significant, lower 1 
incidence of cardiac blocks and/or Q waves and/or pacemaker implantation; active 2 
disease, as defined by a EScSG activity index ≥3 at enrollment  with a higher incidence of 3 
a reduced LVEF and/or CHF. 4 
We underwent our prospective study because of the commonly shared opinion on the 5 
implication of ischemia/reperfusion events in the induction of myocardial fibrosis in SSc,[1-6 
4] as well as the evidence emerged by short term trials and retrospective observational 7 
studies suggesting a beneficial effect of vasodilators on cardiac vascularization and 8 
function in the disease.[5-11] We could not confirm the retrospectively detected  9 
association between vasodilators use and a preserved LVEF,[10] neither we detected any 10 
association between vasodilators and a reduced incidence of cardiac blocks and/or Q 11 
waves and/or pacemaker implantation, which are distinct manifestations of myocardial 12 
fibrosis or of a therapeutic intervention promoted by its consequences.[12] Nevertheless, 13 
we pointed out an association between vasodilators and a lower incidence of ventricular 14 
arrhythmias, which likely depend on ischemic processes.[13,14] This result deserves to be 15 
underlined since ventricular arrhythmias have long been known to be associated with a 16 
poor prognosis in SSc.[13-14,21] 17 
Investigating different aspects potentially associated with the incidence of cardiac events, 18 
we happened to point out an unexpected protective role of low dose ASA and an 19 
unfavourable prognostic role of the EScSG activity index.                                                                                       20 
Low dose ASA is currently prescribed to patients with a high risk of coronary artery 21 
disease.[23] Moreover, it has been recently reported to be associated with a decrease in 22 
the occurrence of major cardiovascular events (i.e. myocardial infarction and stroke) in 23 
patients with systemic lupus erythematosus[27-28] and rheumatoid arthritis.[29] It might, 24 
therefore, be hypothesized that the associations detected between the reduction in the 25 
occurrence of distinct cardiac events and low dose ASA do not depend on a potential 26 
protective effect on small intramyocardial coronary artery disease. Nevertheless, platelet 27 
activation has been reported to play a role of both vascular and fibrotic manifestations of 28 
SSc.[30] Moreover, markers of platelet activation have long been known to be responsive 29 
to antiplatelet therapy.[31]                                                                                                                                           30 
As far as EScSG activity index, Nevskaya et al.[19] have recently reported a predictive role 31 
of the severity heart disease accrual by its adjusted mean over 3 years. Our results seem 32 
to indicate that even a single evaluation might have a prognostic meaning. This result 33 
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prospects that achieving a EScSG activity index≥3 might be a target at least in clinical 1 
practice. 2 
In the original design of our study, we had envisaged 3 treatment arms i.e. CCB, ACEinh, 3 
CCB +ACEinh. Actually, we had not considered the possibility of a SSc patient who is not 4 
prescribed any vasodilator drug. This does not appear to be the case, our data on 5 
prospectively enrolled patients from 20 EUSTAR centres confirming those reported by the 6 
German SSc network highlighting the high percentage of SSc patients who do not receive 7 
any vasoactive therapy.[32] 8 
The observational nature of the study does not allow to prospect any cause/effect 9 
relationship. Well designed Randomised Controlled Trials (RCTs) are needed to either 10 
support or refuse any therapeutic role of vasodilators and low dose ASA in the prevention 11 
of myocardial disease in SSc patients. In addition, the variable, non-standardised length of 12 
follow-up represents a limitation, that, however, appears to be balanced by the long 13 
cumulative duration of follow-up (914 patient/years) and its median time (2.4 years). 14 
Vascular disease has long been considered a pathological hallmark of SSc.[33]  The low 15 
incidence of withdrawls from vasodilator therapy and low dose ASA in our study, even if  16 
waiting for the results of  properly designed RCTs, might  suggest to consider adding low 17 
dose ASA and a vasodilator agent to the therapeutic strategy of  any SSc patients. In that  18 
regard, given the apparent protective role of CCB for SRC on one side,[34] and the 19 
increased risk of death associated with previous exposure to ACEinh in patients 20 
developing a SRC,[35] it appears advisable to start with a CCB and to add an ACEinh in 21 
patients with diastolic dysfunction for the known effect of the latter on ventricular filling.[26]                                                                                                               22 
In conclusion, our prospective, observational study suggests a protective role of 23 
vasodilators and low dose ASA on distinct manifestations of SSc myocardial disease and 24 
prospects the opportunity to conduct well designed RCTs on both therapeutic strategies. 25 
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Key messages: 6 
What is already known about this subject? 7 
- Short term studies have underlined a beneficial effect of calcium channel blockers (CCB) 8 
and other vasodilators including angiotensin converting enzyme inhibitors (ACEinh) on 9 
cardiac vascularization and function in Systemic Sclerosis (SSc).                                                                         10 
- However, the role of vasodilative agents in the prevention of primary myocardial disease 11 
has not yet been defined. 12 
What does this study add? 13 
-This is the first observational, long term study to investigate the association between  14 
vasodilators use and the occurrence of disease manifestations probably or potentially 15 
related to myocardial fibrosis.                                                                                                                                16 
- Associations between vasodilators and low dose ASA use and a decrease in the 17 
incidence of distinct manifestations have emerged.  18 
How might this impact on clinical practice? 19 
-Our study could prompt clinicians to consider adding a vasodilator agent and low dose 20 
ASA to the therapeutic strategy of any SSc patient. 21 
 22 
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